Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 05/29/2024

List of Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies

Clinical Use

The clinical research supply of the CTEP agents, below, is largely for the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ETCTN), however investigators from certain NCI-designated Cancer Centers not affiliated with these networks may submit a LOI. If approved, investigators may receive full ETCTN support for the clinical trial. Non-ETCTN NCI Cancer Centers will also be able to compete for administrative supplements to enroll patients on select ETCTN phase 2 trials through the NCI Early Drug Development Opportunity Program (EDDOP).

NOTE: It is very important for anyone thinking of developing an LOI to first communicate with the appropriate drug monitor, as listed on the table, before initiating work on the LOI.

Non-Clinical Use

The CTEP agents, below, are available to all requestors after NCI receives the industry supplier’s approval for the proposed research. For requests other than agents from AstraZeneca, please use the Non-clinical Request Form found at: Non-clinical Request. For AstraZeneca agents please use the AZ Non-clinical Request Form. For any other questions, please email NCICTEPRequests@mail.nih.gov.

OTHER AGENTS: If the agent you are looking for is not on this list please also check the NCI Formulary.

NOTE: this list can be sorted by clicking on any of the header names. For an Excel Spreadsheet of these agents please click here.

CAUTION: The table is not a 'live' document. It is updated about 4 times per year, so should never be assumed to contain the most recent changes. Please feel free to contact the appropriate drug monitor, as listed on the table to confirm accuracy.

Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies as of 05/29/2024

Agent Name Alternate Name Pharmaceutical Collaborator NSC Number Drug Monitor Mechanism of Action Targets Classes
Acalabrutinib   AstraZeneca 806311 Ivy selectively inhibits Bruton’s tyrosine kinase (BTK) with minimal effects on TEC, EGFR, and ITK signaling. Bruton’s tyrosine kinase (BTK) Small Molecule
Actimab-A   Actinium Pharmaceuticals, Inc. 843488 Pelosof Antibody Radioconjugate comprising the alpha-particle emitting radionuclide actinium-225 (Ac225) conjugated to lintuzumab, a humanized anti-CD33 monoclonal antibody CD33+ myeloid-derived suppressor cells (MDSCs) Antibody Radioconjugate
AMG510 Satorasib Amgen 825510 Pelosof Inhibits G12C-mutated KRAS mutated KRAS protein Small Molecule
Amivantamab JNJ-61186372 Janssen Scientific Affairs, LLC 842127 Pickett Inhibits EGFR and MET signaling Extracellular domains of EGFR and MET Bispecific Antibody
APG-12522 Pelcitoclax Ascentage 831685 Gore Inhibits B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma — extra-large (Bcl-xL) anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 Small Molecule
ASTX660 Tolinapant Taiho Oncology 842224 Gore A dual antagonist of inhibitors of apoptosis proteins X-linked inhibitor of apoptosis protein (XIAP) and (cellular inhibitor of apoptosis proteins 1/2 (cIAP1/2) Inhibitors of XIAP and cIAP1/2 Small Molecule
ASTX7273 Fixed-Dose Combination of cedazuridine and decitabine Taiho Oncology 820631 Pelosof DNA methyltransferase (DNMT) inhibitor DNA methyltransferase Small Molecule
Atezolizumab MPDL3280A Genentech 783608 Chen Targets PD-L1 expressed on tumor and infiltrating immune cells, preventing binding to PD-1 and B7.1 programmed cell death ligand 1 (PD-L1) Monoclonal Antibody
AZD5363 Capivasertib AstraZeneca 782347 Said Inhibits all AKT isoforms AKT Small Molecule
Balstilimab6 AGEN2034 Agenus 853950 Pickett Binds PD-1 to prevent the interaction between the receptor and its ligands. PD-1 Monoclonal Antibody
Botensilimab AGEN1181 Agenus 853990 Pickett Binds to CTLA-4 to inhibits the CTLA-4-mediated downregulation of T-cell activation. CTLA-4 Monoclonal Antibody
Belinostat PXD 101 Acrotech Biopharma 726630 Pelosof Histone deacetylase inhibition Histone deacetylase Hydroxamic acid
Bevacizumab rhuMAb VEGF Genentech 704865 Pickett Binds VEGF to prevent its binding to VEGFR; angiogenesis inhibition VEGF Monoclonal Antibody(Humanized)
Blinatumomab AMG-103, MT-103 Amgen 765986 Pickett bispecific (BiTE specific) antibody targeting CD19 CD19 Monoclonal Antibody
Bortezomib PS-341 Takeda/Millennium 681239 Said 26S proteosome inhibition (stabilizes p53, p27; inhibits NF-kB activation; alters cyclin-mediated regulation of cell cycle progression) Proteosome Inhibitor(Proteosome - Complex) Small Molecule
Brentuximab vedotin SGN-35 Seattle Genetics 749710 Pickett An antibody drug conjugate targeting CD30 and using an MMAE payload CD30 Antibody-Drug Conjugate
CA-4948 Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Inhibitor Curis, Inc. 824184 Pickett Inhibits TLR and IL-1R signaling; Inhibits myddosome signaling; inhibits NFkB activity IRAK4 and IRAK4-L Small Molecule
Cabozantinib XL-184 Exelixis 761968 Said c-Met; VEGFR2 inhibition c-Met; VEGFR2 Small Molecule
CBX-121 alphalex-exatecan Cybrexa 2, Inc 828474 Said Alphalex conjugate that contains a topoisomerase I inhibitor exatecan Topoisomerases I Peptide Drug Conjugate
CDX-1140   Celldex 841752 Pickett Agonist anti-CD40 monoclonal antibody that inhibits cancer cell proliferation or triggers apoptotic cell death Human CD40 Monoclonal antibody (mAb)
Cediranib1 AZD2171 AstraZeneca 732208 Ivy Angiogenesis inhibitor, VEGFR1, VEGFR2, VEGFR3, PDGFR alpha and beta, FGFR1 VEGFRs, PDGFRs, FGFR1 Small Molecule
Cemiplimab REGN2810 Regeneron 788843 Pickett Inhibits programmed death receptor-1 Programmed cell death 1 (PD-1) on the surface of immune cells Monoclonal Antibody
Cirtuvivint   Biosplice Therapeutics, Inc 835563 Gore Inhibits CDC-Like Kinases (CLK) and Dual-Specificity Tyrosine-Regulated Kinases (DYRK) CLK/DYRK kinase Small Molecule
Dabrafenib mesylate1 GSK2118436B Novartis 763760 Chen BRAF inhibition of BRAFV600 mutations BRAF Small Molecule
Darolutamide BAY-1841788 Bayer 815949 Pelosof A novel nonsteroidal androgen receptor (AR) antagonist androgen receptor (AR) Small Molecule
DAY101 Tovorafenib Day One Biopharmaceuticals, Inc. 800798 Said A selective Type II pan-RAF kinase inhibitor pan-RAF kinase Small Molecule
Dinutuximab Ch14.18 United Therapeutics 764038 Chen Antibody against GD2 GD2 Monoclonal Antibody (chimeric)
Durvalumab MEDI4736 AstraZeneca/Medimune 778709 Chen Check point inhibitor. Antibody against programmed cell death ligand 1 (PD-L1) PD-L1 Monoclonal Antibody
Fianlimab   Regeneron 847987 Pickett Inhibits immune checkpoint receptor LAG-3 LAG-3 on T cells Monoclonal Antibody
Ganitumab1 AMG-479 ImmunityBio 750008 Chen Insulin-like Growth Factor-1 Receptor (IGF-1R) antibody IGF-1R Small Molecule
Giredestrant GDC-9545 Genentech 840836 Pickett Selective estrogen receptor degrader (SERD) Competitively binds to the ligand binding-domain (LBD) of both wild-type and mutant estrogen receptor (ER) Small Molecule
Glofitamab RO7082859 Genetech 845088 Pickett promotes T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells bivalency for CD20 on B cells and monovalency for CD3 on T cells. Bispecific antibody
GMI-1271 uproleselan GlycoMimetics 801708 Gore Inhibits binding of tumor cells to stroma, potentially inhibiting adherence-mediated chemoresistance. E-selectin Antineoplastic, Antithrombotic, Glycolipid, Small Molecule
Iberdomide   Bristol Myers Squibb 833899 Said Immunomodulatory therapeutic Induces degradation of transcription factors Aiolos and Ikaros Small Molecule
Ibrutinib PCI-32765 Pharmacylics 748645 Ivy Bruton’s Tyrosine Kinase (BTK) inhibitor BTK Small Molecule
idUrd Prodrug IPdR NCI 726188 Pelosof Prodrug of iododeoxyuridine DNA polymerase Small Molecule
IMC-F106C   Immunocore 853198 Streicher An immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC) for the treatment of cancers positive for the tumor-associated antigen PRAME. TCR bispecific protein targeting CD3 and PRAME Monoclonal Antibody
Inavolisib GDC-0077 Genentech 843575 Said Selectively inhibits the Class I PI3Kα isoform (p110α), with minimal inhibition of the Class I PI3K β, γ, and δ isoforms Class I PI3Kα isoform (p110α) Small Molecule
Interleukin-12 IL-12 NCI 672423 Streicher Made mainly by dendritic cells and macrophages. Causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels. Binds to the IL-12 receptor found on activated T cells Upon binding, IL-12R-β2 provides binding sites for Tyk2 and Jak2, activating STAT4 Pleiotropic Cytokine
Interleukin-15 IL-15 NCI 745101 Streicher Cytokine that regulates T and natural killer cell activation and proliferation. Shares many biological activities with interleukin 2 Activates JAK kinases, and phosphorylation/activation of transcription activators STAT3, STAT5 and STAT6. Cytokine
Ipatasertib1 GDC-0068 Genentech 781451 Said an ATP-competitive AKT inhibitor, blocks the phosphoinositide 3-kinase (PI3K)/AKT pathway all three isoforms of AKT small molecule
Larotrectinib   Bayer 788607 Pelosof Highly-selective, tropomyosin receptor kinase (TRK) inhibitor NTRK-1, NTRK-2, NTRK-3 gene fusions; TrkA/B/C fusion proteins Small Molecule
Lutetium Lu177 Dotatate Novartis 815530 Pelosof Radiopharmaceutical that binds to somatostatin receptor, is internalized and accumulates in lysosomes. Somatostatin receptor Radiopharmaceutical
M17744 VXc 400 or VRT 1363004 EMD Serono (Merck KGaA) 831851 Gore Selectively inhibits ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase ATR Small Molecule
M3814 MSC2490484A EMD Serono (Merck KGaA) 802447 Gore DNA-PK inhibition, delays DNA repair of the DSB pathway in solid tumors and hematologic malignancies DNA-dependent protein kinase (DNA-PK) Small Molecule
Methoxyamine hydrochloride TRC-102 Tracon 3801 Gore Small molecule inhibitor of the DNA Base Excision Repair (BER) pathway BER Small Molecule
METxMET REGN5093 Regeneron 849708 Pickett Binds to two distinct epitopes of MET, thus blocking HGF binding and induces internalization and degradation of MET MET (receptor tyrosine kinase) Bispecific Antibody
Mezigdomide   Bristol Myers Squibb Company   Said Cereblon E3 ligase modulator (CELMoD), IKAROS family zinc finger 1 and 3 inhibitor, protein degrader cereblon (CRBN)-E3 ligase, IKAROS family zinc finger 1&3 Small Molecule
Mirdametinib   SpringWorks Therapeutics, Inc. 755770 Said Inhibits MAPK signaling pathway MEK1 and MEK2 Small Molecule
Mogamulizumab KW-0761 Kyowa Kirin 791064 Chen Defucosylated humanized IgG1 mAb against C-C chemokine receptor 4 (CCR4) C-C chemokine receptor 4 Monoclonal Antibody
Mosunetuzumab   Genentech 833090 Pickett Simultaneously targets CD20 on B-cells and CD3 on T-cells by redirecting endogenous T-cells to engage and eliminate tumor-specific CD20-expressing B-cells. CD20 on B-cells and CD3 on T-cells Full length IgG1 antibody
Nemvaleukin Alfa   Alkermes, Inc. 836408 Streicher Binds to the IL-2R complex to preferentially activate memory cytotoxic CD8+T cells and natural killer (NK) cells without expanding CD4+ Tregs. IL-2R complex Engineered IL-2 variant
Osimertinib AZD9291 AstraZeneca 781254 Said 3rd generation epidermal growth factor receptor mutation (mEGFR) inhibitor mEGFR and the dominant acquired T790M resistance mutation Small Molecule
Pembrolizumab MK-3475 Merck 776864 Streicher Humanized IgG4 mAb against programmed death 1 receptor (PD-1) PD-1 Antibody
Pidnarulex CX-5461 Senhwa Biosciences, Inc. 845292 Gore G-Quadruplex-stabilizer (Quinolone Derivative) it causes replication fork stalling and promotes DNA damage resulting in cell death homologous recombination deficiency (HRD) tumors. Small Molecule
Radium223 Radium223 Bayer 793433 Pelosof alpha particle-emitting radionuclides   Radiopharmaceutical
Relatlimab5 BMS-986016 Bristol-Myers Squibb 783201 Streicher inhibitor of the LAG-3 checkpoint receptor LAG-3 Monoclonal Antibody
Sapanisertib FTH-003 Faeth therapeutics, Inc. 768435 Said Inhibits Rapamycin complex1/2 (TORC1/TORC2) kinase TORC1/TORC2 Small Molecule
Savolitinib AZD6094 AstraZeneca 785348 Pelosof specific, small molecule inhibitor of the MET receptor kinase cMet Small Molecule
Selumetinib1 AZD6244 AstraZeneca 748727 Pelosof MAPK/ERK Kinase (MEK) inhibition MEK enzyme Small Molecule
Sorafenib tosylate BAY 43-9006, BAY 54-9085 Bayer 724772 Gore Raf kinase inhibitor, receptor tyrosine kinase (RTK) inhibitor (VEGFR-2, Flt3, cKIT), PDGFR inhibitor, Ret inhibitor, angiogenesis inhibition Signal Transduction(Raf kinase, VEGFR2, PDGFR, c-kit - Protein) Small Molecule(Bi-aryl urea)
Sunitinib malate SU011248, L-malate Pfizer 736511 Gore Angionenesis inhibitor: PDGFR alpha/beta,VEGFR 1,2,3,KIT, RET, CSF-1R,FLT3 VEGF2, c-KIT, Flt-3, and PDGFR beta Small Molecule
talazoparib BMN 673 (MDV 38000) Pfizer 771561 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, strong trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP 1 and 2 inhibitor Small Molecule
Tazemetostat   Epizyme/Ipsen 791066 Pelosof Inhibits Enhancer of zeste homolog 2 (EZH2) EZH2 Small Molecule
Teclistamab   Janssen Research and Development, LLC 840815 Pickett Bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and BCMA expressed on the surface of malignant multiple myeloma B lineage cells and leads to cell death of the BCMA+ cells BCMA+ malignant B cells Bispecific antibody
Tin-117m-DTPA   Serene   Pelosof Radiopharmaceutical that selectively accumulates in bone metastases   Radiopharmaceutical
Tiragolumab RO7092284 Genentech 827799 Chen Binds and inibits T cell immunoreceptor with Ig and ITIM domains (TIGIT) expressed on the subsets of activated T cells, natural killer (NK) cells and tumor-infiltrating immune cells. T cell immunoreceptor with Ig and ITIM domains Monoclonal antibody
Trametinib1 GSK112021 Novartis 763093 Chen Potent and highly selective inhibitor of MEK1/2 activation and kinase activity MEK enzyme Small Molecule
Trastuzumab deruxtecan DS-8201a Daiichi Sankyo 807708 Pickett HER2-targeted antibody-drug conjugate - inhibits topoisomerase I which leads to apoptosis of the target cells Human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody-drug conjugate
TRC-105   Tracon 754227 Gore monoclonal antibody for CD105 CD105 Monclonal Antibody
Triapine   Nanopharmaceutics, Inc. 663249 Ivy Ribonucleotide reductase (RR) inhibitor inhibits the metal binding subunit (M2) of RR, which is essential for DNA synthesis and repair. DNA Synthesis(RR M2 subunit - Enzyme) Small Molecule
Varlilumab CDX-1127 Celldex 778372 Chen fully human monoclonal antibody that targets CD27 CD27 and activates tumor specific T cells Monocloncal Antibody
Venetoclax ABT-199 Abbvie/Genentech 766270 Gore Bcl-2-selective inhibitor that disrupts Bcl-2 signaling in cells and rapidly induces multiple hallmarks of apoptotic cell death in Bcl-2-dependent tumor cells Bcl-2 and with lower affinity to Bcl-XL and Bcl-w Small Molecule
VXc-9841 M9831 EMD Serono (Merck KGaA) 789705 Gore DNA-PK inhibition DNA-dependent protein kinase (DNA-PK) Small Molecule
ZEN-3694 ZEN003694 Zenith Epigenetics Ltd. 824453 Pelosof epigenetically regulates gene expression through BET inhibition, targeting BET proteins leads to inhibition of tumor growth in multiple cancer types, through cell cycle arrest and induction of senescence and apoptosis.
Bromodomain and Extra-Terminal motif (BET) inhibitor Small Molecule
Z-endoxifen HCI   NCI 750393 Streicher Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is an anti-estrogen Targets estrogen receptor-alpha Small Molecule
Ziv-aflibercept VEGF-Trap Sanofi Aventis 724770 Ivy Chimeric IgG-VEGFR-1+VEGFR-2 molecule binds to VEGF to prevent its binding to VEGFR-1(Flt-1) and VEGFR-2 (KDR/Flk-1) receptors; angiogenesis inhibition VEGF Protein

1 - Non-clinical requests only
2 - Only available for solid tumor indications
3 - Only available for clinical studies
4 - Discuss with Dr. Gore before preparing/submitting an LOI
5 - Available only for combinations with nivolumab +/- ipilimumab. Please contact the drug monitor prior to requesting this agent
6 - In Combination with botensilimab only